

Intrinsic Bioprobes and Bruker Daltonics Announce Strategic Collaboration

TEMPE, Ariz. and BILLERICA, Mass., Sep 21, 2001: Intrinsic Bioprobes Inc. (IBI) and Bruker Daltonics Inc. (NASDAQ: BDAL) today announced a strategic collaboration and agreement in the field of MALDI-TOF mass spectrometry. As part of the agreement, Bruker Daltonics' autoflex(TM) MALDI-TOF mass spectrometer will become an integral portion of Intrinsic Bioprobes' MASSAY(TM) system. MASSAY also incorporates IBI's Bioreactive Probes(TM) and Mass Spectrometric Immunoassay(TM) technologies, automation protocols and robotics handling. Financial terms of the agreement were not disclosed. Dr. Randall W. Nelson, President and CEO of Intrinsic Bioprobes, said: "The autoflex MALDI-TOF mass spectrometer possesses the high-throughput capabilities and performance criteria needed for the next phase in proteome analysis. With the autoflex at its core, the MASSAY System will be able to perform fully automated high-throughput analyses of thousands of targeted biological assays per day. As such, we believe that the MASSAY System represents a major technological innovation and answers the need for advanced technologies in the field of targeted proteomics."

John Wronka, Ph.D., Vice-President and U.S. General Manager of Bruker Daltonics, is enthusiastic about the agreement: "Dr. Nelson and his IBI team are leaders in the development of bioreactive probes and immunoassays based on mass spectrometry for the detection of specific proteins and biomarkers. This strategic collaboration - really a natural combination of IBI technologies with our mass spectrometry systems - gives us both additional potential for growth in the high-throughput analysis of targeted proteins in complex mixtures."

About Intrinsic Bioprobes

Intrinsic Bioprobes Inc. is a privately held biotechnology company focused on developing innovative technologies for rapid and sensitive proteome analysis. The company's proprietary technologies consist of Bioreactive Mass Spectrometer Probes (BRP(TM)), devices for rapid, sensitive and accurate protein characterization, and Mass Spectrometric Immunoassay (MSIA(TM)), a high-performance approach for the selective isolation of proteins from complex biological matrices. These core technologies are

incorporated into the MASSAY System, a high throughput mass spectrometry approach geared for rapid proteome analysis. For more information about Intrinsic Bioprobes, please visit <http://www.intrinsicbio.com>.

About Bruker Daltonics

Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions and government agencies. Bruker Daltonics has diverse technology platforms that integrate automated sample preparation and clean-up, advanced front-end AnchorChip MALDI targets and API source technology with cutting-edge proprietary MALDI-TOF, MALDI-TOF/TOF, ESI-TOF, ESI-Q-q-TOF, ion trap and FTMS mass analyzers, as well as analysis and bioinformatics software. Bruker Daltonics is also a worldwide leader in supplying mass spectrometry-based systems for substance detection and pathogen identification in security, defense and anti-terrorism applications.

Cautionary Statement

All statements in this press release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements regarding Bruker Daltonics' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially for Bruker Daltonics from those projected, including, but not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Bruker Daltonics' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

CONTACT: Intrinsic Bioprobes Inc.:
 Ed Beaudett, Director of Business Development
 (480) 804-1778
 Ed@intrinsicbio.com
 or
 Bruker Daltonics Inc.:
 Michael Willett, Investor Relations Officer
 (978) 663-3660, ext. 1411
 michael.willett@bdal.com